CELLBION CO LTD has a total of 12 patent applications. Its first patent ever was published in 2012. It filed its patents most often in Republic of Korea, WIPO (World Intellectual Property Organization) and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and measurement are AVENTIS PHARMA HAINAN CO LTD, QUESTCOR PHARMACEUTICALS INC and LEO LAB LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | Republic of Korea | 3 | |
#2 | WIPO (World Intellectual Property Organization) | 3 | |
#3 | EPO (European Patent Office) | 2 | |
#4 | Australia | 1 | |
#5 | Canada | 1 | |
#6 | China | 1 | |
#7 | United States | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Measurement | |
#4 | Micro-structure and nano-technology | |
#5 | Machines |
# | Name | Total Patents |
---|---|---|
#1 | Jeong Jae Min | 7 |
#2 | Lee Yun-Sang | 6 |
#3 | Moon Sung-Hyun | 6 |
#4 | Choi Nam Song | 3 |
#5 | Ahn Soon Kil | 3 |
#6 | Shin Young June | 3 |
#7 | Han Cheol Kyu | 3 |
#8 | Han Chang Kyun | 3 |
#9 | Auh Jin | 3 |
#10 | Kim Kweon | 2 |
Publication | Filing date | Title |
---|---|---|
KR20200050207A | p-Boronophenylalanine composition for Boron Neutron Capture Therapy and preparing method thereof | |
KR20140050622A | Novel compounds or pharmaceutically acceptable salts thereof inhibiting activity of 11β-HSD1 (11β-Hydroxysteroid dehydrogenase type 1) enzyme, preparation method thereof and pharmaceutical composition containing the same as an active ingredient | |
KR20140026598A | Novel compounds or pharmaceutically acceptable salts thereof inhibiting activity of 11β-HSD1 (11β-Hydroxysteroid dehydrogenase type 1) enzyme, preparation method thereof and pharmaceutical composition containing the same as an active ingredient |